LXRX - Lexicon Pharmaceuticals Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

324.4M

Cash

355.6M

Avg Qtr Burn

-46.35M

Short % of Float

16.83%

Insider Ownership

1.15%

Institutional Own.

72.83%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
INPEFA™ (SOTAGLIFLOZIN) Details Heart disease, Heart failure	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XERMELO® (telotristat ethyl) Details Carcinoid syndrome diarrhea	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sotagliflozin (ZYNQUISTA™) (SGLT1/SGLT2) Details Diabetes, Type 1 diabetes	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sotagliflozin (ZYNQUISTA™) (SGLT1/SGLT2) Details Hypertrophic cardiomyopathies	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LX9211 Details Diabetic peripheral neuropathy, Neuropathy	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.